Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13761437 | 0.82 | ALDH1A1 (0.65) | GAAALDH1A1MAPTHTTKDM4E | |
| SCHEMBL5455321 | 0.82 | SMN1; SMN2 (0.66) | GAAALDH1A1MAPTHTTKDM4E | |
| SCHEMBL10099725 | 0.81 | GAA (0.83) | GAAALDH1A1MAPTHTTKDM4E | |
| SCHEMBL11072927 | 0.81 | CYP1A2 (0.74) | GAAALDH1A1MAPTHTTKDM4E | |
| SCHEMBL8611488 | 0.81 | ALDH1A1 (0.81) | GAAALDH1A1MAPTHTTKDM4E | |
| SCHEMBL14386215 | 0.81 | SMN1; SMN2 (0.68) | GAAALDH1A1MAPTHTTKDM4E | |
| SCHEMBL8979285 | 0.81 | LMNA (0.70) | GAAALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL14386106 | 0.80 | LMNA (0.72) | GAAALDH1A1MAPTHTTKDM4E | |
| SCHEMBL6068286 | 0.80 | EPHX2 (0.58) | GAAALDH1A1MAPTHTTKDM4E | |
| SCHEMBL1275764 | 0.80 | KMT2A (0.72) | GAAALDH1A1MAPTHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263167-A1 | METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-08-24 | — | — | US | disclosed |
| US-11700855-B2 | Method for preventing or reducing growth of a microorganism on a surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-18 | — | — | US | disclosed |
| US-20210061670-A1 | METHOD FOR PREVENTING OR REDUCING GROWTH OF A MICROORGANISM ON A SURFACE | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-03-04 | — | — | US | disclosed |
| US-10934176-B2 | Methods of degrading organic pollutants and preventing or treating microbe using Bi2S3-CdS particles | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-03-02 | — | — | US | disclosed |
| US-20200102228-A1 | METHODS OF DEGRADING ORGANIC POLLUTANTS AND PREVENTING OR TREATING MICROBE USING Bi2S3-CdS PARTICLES | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2020-04-02 | — | — | US | disclosed |
| US-10105687-B1 | Heterostructured Bi2S3—ZnS photocatalysts and methods thereof | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2018-10-23 | — | — | US | disclosed |
| US-7135492-B2 | Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion | WYETH (US) | 2006-11-14 | — | — | US | disclosed |
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | WYETH | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | FFAR4, FFAR1, MSR1 | GAA 4801/4885ALDH1A1 896/4885MAPT 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.